Compare Cipla with Lupin - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs LUPIN - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA LUPIN CIPLA/
LUPIN
 
P/E (TTM) x 37.1 -297.7 - View Chart
P/BV x 4.3 3.9 111.0% View Chart
Dividend Yield % 0.5 0.6 85.0%  

Financials

 CIPLA   LUPIN
EQUITY SHARE DATA
    CIPLA
Mar-20
LUPIN
Mar-20
CIPLA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs586882 66.4%   
Low Rs357505 70.7%   
Sales per share (Unadj.) Rs207.0339.4 61.0%  
Earnings per share (Unadj.) Rs18.6-5.9 -312.7%  
Cash flow per share (Unadj.) Rs33.215.5 214.4%  
Dividends per share (Unadj.) Rs4.006.00 66.7%  
Dividend yield (eoy) %0.80.9 98.1%  
Book value per share (Unadj.) Rs195.5276.7 70.6%  
Shares outstanding (eoy) m806.35453.00 178.0%   
Bonus/Rights/Conversions ESOSESOP-  
Price / Sales ratio x2.32.0 111.4%   
Avg P/E ratio x25.3-116.6 -21.7%  
P/CF ratio (eoy) x14.244.8 31.7%  
Price / Book Value ratio x2.42.5 96.2%  
Dividend payout %21.5-100.9 -21.3%   
Avg Mkt Cap Rs m379,912314,201 120.9%   
No. of employees `00025.818.3 141.2%   
Total wages/salary Rs m30,27029,868 101.3%   
Avg. sales/employee Rs Th6,459.68,400.6 76.9%   
Avg. wages/employee Rs Th1,171.21,632.0 71.8%   
Avg. net profit/employee Rs Th580.2-147.2 -394.2%   
INCOME DATA
Net Sales Rs m166,949153,748 108.6%  
Other income Rs m3,4424,838 71.2%   
Total revenues Rs m170,391158,585 107.4%   
Gross profit Rs m32,06024,849 129.0%  
Depreciation Rs m11,7479,702 121.1%   
Interest Rs m1,9743,630 54.4%   
Profit before tax Rs m21,78216,355 133.2%   
Minority Interest Rs m-4754 -12,169.2%   
Prior Period Items Rs m039 0.0%   
Extraordinary Inc (Exp) Rs m0-7,521 0.0%   
Tax Rs m6,31211,571 54.5%   
Profit after tax Rs m14,995-2,694 -556.6%  
Gross profit margin %19.216.2 118.8%  
Effective tax rate %29.070.8 41.0%   
Net profit margin %9.0-1.8 -512.6%  
BALANCE SHEET DATA
Current assets Rs m117,038154,132 75.9%   
Current liabilities Rs m43,93192,252 47.6%   
Net working cap to sales %43.840.2 108.8%  
Current ratio x2.71.7 159.5%  
Inventory Days Days9682 116.6%  
Debtors Days Days85129 65.8%  
Net fixed assets Rs m107,42489,082 120.6%   
Share capital Rs m1,613906 178.0%   
"Free" reserves Rs m156,018124,461 125.4%   
Net worth Rs m157,630125,367 125.7%   
Long term debt Rs m23,69317,933 132.1%   
Total assets Rs m236,626249,839 94.7%  
Interest coverage x12.05.5 218.6%   
Debt to equity ratio x0.20.1 105.1%  
Sales to assets ratio x0.70.6 114.6%   
Return on assets %7.20.4 1,914.3%  
Return on equity %9.5-2.1 -442.7%  
Return on capital %12.88.7 147.1%  
Exports to sales %33.00-   
Imports to sales %00-   
Exports (fob) Rs m55,175NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,03651,450 108.9%   
Fx outflow Rs m6,76419,470 34.7%   
Net fx Rs m49,27231,980 154.1%   
CASH FLOW
From Operations Rs m30,68514,688 208.9%  
From Investments Rs m1,04011,070 9.4%  
From Financial Activity Rs m-29,488-8,906 331.1%  
Net Cashflow Rs m2,34016,853 13.9%  

Share Holding

Indian Promoters % 16.0 46.6 34.3%  
Foreign collaborators % 20.8 0.2 10,400.0%  
Indian inst/Mut Fund % 12.2 11.3 108.0%  
FIIs % 23.7 31.9 74.3%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 10.1 259.4%  
Shareholders   161,166 98,259 164.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   DR. DATSONS LABS  DISHMAN PHARMA  J.B.CHEMICALS  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  

Compare CIPLA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

5 Reasons Why Sensex and Nifty Plunged 2% Today(Closing)

Indian share markets witnessed heavy selling pressure today despite the US administration saying it would bring a stimulus package even without the opposition's support.

Related Views on News

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

One Chart to See Before You Sell(Fast Profits Daily)

Jan 22, 2021

In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.

Invest in the Multibaggers of 2021 and Beyond(Profit Hunter)

Jan 21, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jan 27, 2021 (Close)

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS